Wang C, et al. - In the patients with thyroid-associated ophthalmopathy (TAO), the impact of before - after rituximab (RTX) therapy was compared by the experts. When compared to the initial value, there was a decline in clinical activity score (CAS) at 1,3,6,12 month following RTX treatment. Thyrotropin receptor antibody (TRAb) level decreased at 6,12 month, proptosis improvement at least 1 month, interleukin-6 (IL-6) level remained unchanged at 6 month. The thyroid stimulating hormone (TSH) level was noted to be decreased at 3 month, however, it remained unchanged at 12 month. Therefore, the preliminary effects of RTX treatment on TAO were noted to be promising.